OptimizeRx reports Q2 EPS 24c, consensus 2c

Reports Q2 revenue $29.2M, consensus $22.89M. The company said, “Our year-to-date results continue to deliver profitable growth ahead of expectations. Contracted revenue is now up more than 30% year-over-year, positioning us for a strong finish to the second half. We believe this momentum is a direct result of our disciplined focus on operational excellence, our relentless commitment to delivering exceptional customer experiences, our utilization of a market-leading patient finding AI technology, and our deepening partnerships across the ecosystem-all of which are contributing to meaningful, long-term shareholder value. As our second quarter results clearly highlight, we are well on our way to becoming a Rule of 40 company. Given our strong performance and positive outlook, I’m pleased to announce that we are raising our full-year guidance.”